eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2022
vol. 26
 
Share:
Share:
more
 
 
abstract:
Original paper

Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study

Asmaa Hussein Mohamed
1
,
Mariem A. Elfeky
1
,
Shereen Elshorbagy
2
,
Nabila Hefzi
3
,
Tamer Oraby
4
,
Waleed A. Abdelhady
5
,
Mahmoud Sharaf Eldein
6
,
Ahmed Embaby
6
,
Ehab M. Oraby
7

1.
Department of Pathology, Zagazig University Faculty of Medicine, Zagazig, Egypt
2.
Department of Medical Oncology, Faculty of Medicine, Zagazig University Zagazig, Egypt
3.
Department of Clinical Oncology Oncology, Faculty of Medicine, Zagazig University Zagazig, Egypt
4.
Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Zagazig, Egypt
5.
Department of General Surgery, Faculty of Medicine, Zagazig, Egypt
6.
Department of Internal Medicine, Faculty of Medicine, Zagazig, Egypt
7.
Department of General Surgery, Faculty of Medicine, Benha, Egypt
Contemp Oncol (Pozn) 2022; 26 (1): 49–58
Online publish date: 2022/03/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Diffuse large B-cell non- Hodgkin lymphoma (DLBCL) is the largest common category of adult lymphoma. Recurrence and treatment resistance occurs in one-third of cases, triggering them to the progressive stage of DLBCL after treatment. Detection of novel predictive and prognostic biomarkers leads to improvement of its treatment and prognosis.

Aim of the study
To assess the prognostic roles of protein expression of myeloid differentiation factor 88 (MYD88) and transducin ()-like receptor 1 (TBLR1) in tissues of DLBCL patients.

Material and methods
In the current study we included tissues from 100 cases of DLBCL. For immunohistochemistry, tissues were stained with MYD88 and TBLR1. We followed patients for about 3 years, and then we correlated their expression with clinicopathological and prognostic parameters.

Results
Higher MYD88 and TBLR1 expressions were associated with presence of B symptoms, fever, night sweat, advanced stage, bone marrow involvement and bulky nodal size, presence of extra-nodal extension, unfavourable relapse-free survival, and unfavourable overall survival rates (p < 0.001).

Conclusions
overexpression of MYD88 and TBLR1 expression was present in DLBCL patients and was associated with unfavourable clinicopathological and prognostic parameters.

keywords:

MYD88, TBLR1, immunohistochemistry, diffuse large B-cell lymphoma, prognosis

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.